Albany, NY -- (SBWIRE) -- 10/29/2019 -- Cushing's Syndrome Market Insights, Epidemiology and Market Forecast-2028

1. The endogenous Cushing's Syndrome prevalence is 1/26,000.
2. Cushing's syndrome most commonly affects adults between the ages of 25 to 40.
3. Cushing's disease prevalence maybe 5 to 25 per million per year. In the United States, the prevalence was higher than previously reported in European studies as it was found to affect 6.2 to 7.6 per million person-years.

(Albany, US) DelveInsight launched a new report on Cushing's Syndrome Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Cushing's Syndrome market report covers a descriptive overview and comprehensive insight of the Cushing's Syndrome epidemiology and Cushing's Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Cushing's Syndrome market report provides insights into current and emerging therapies.
3. Cushing's Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Cushing's Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Cushing's Syndrome market.

Request for sample pages

"Cushing's syndrome is at least three times more prevalent in women than in men, and mainly observed during the fourth to sixth decades of life."

The main objectives for the Cushing's syndrome treatment include normalization of cortisol secretion; reversal of the clinical picture; prevention or recovery of the concomitant comorbidities and clinical complications; and long-term disease control without disease recurrence. The attainment of these objectives, however, frequently requires a multimodal Cushing's syndrome treatment approach.

The first-line Cushing's syndrome treatment is, presently, pituitary surgery by the transsphenoidal approach, aiming at the removal of the pituitary tumour. However, aside from the possibility of hypopituitarism, nearly one-third of patients will experience an immediate failure or subsequent relapse during the ten years after surgery.

Therefore, a significant percentage of patients will require a second-line treatment approach. Second-line Cushing's syndrome treatment may be represented by a repeat surgery, which is however associated with a lower chance of success and a higher chance of hypopituitarism compared with the initial surgery, or more radical treatments such as pituitary radiotherapy and bilateral adrenalectomy. Pituitary radiotherapy successfully controls cortisol secretion in more than half of patients and has the advantage of being directed at the pituitary tumour. However, the disadvantages are the latency between treatment and disease control, which may last several years, and the high risk of the occurrence of hypopituitarism. On the other hand, bilateral adrenalectomy is followed by immediately successful disease control in nearly the totality of patients. However, the main disadvantage of the Cushing's syndrome therapeutic approach is the consequent adrenal insufficiency, requiring lifelong glucocorticoid and mineralocorticoid replacement. Moreover, Cushing's syndrome treatment is not directed at the pituitary tumour, which can subsequently keep increasing in size with the possible development of corticotroph tumour progression; prevention of this condition requires periodic monitoring of tumour mass.

The expected launch of Cushing's syndrome emerging therapies will create a positive impact on the Cushing's syndrome treatment landscape during the forecast period (2019-2028). In conclusion, there seems to be a promising growth in Cushing's syndrome market size, which will positively impact the launch of these therapies.

The launch of the emerging therapies is expected to significantly impact Cushing's syndrome treatment scenario in the upcoming years: -
Drugs covered
1. Osilodrostat
2. Relacorilant
3. Levoketoconazole
4. Metyrapone
5. ATR-101
And many others

The key players in Cushing's syndrome market are:
1. Recordati
2. Corcept Therapeutics
3. Strongbridge Biopharma
4. HRA Pharma
5. Millendo Therapeutics
And many others

Table of contents

1. Report Introduction
2. Cushing's Syndrome Market Overview at a Glance
3. Cushing's Syndrome Disease Background and Overview
4. Cushing's Syndrome Epidemiology and Patient Population
5. Cushing's Syndrome Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.2.7. Japan
6. Cushing's Syndrome Treatments & Medical Practices
7. Cushing's Syndrome Marketed Products
7.1. Mifepristone (Korlym): Corcept Therapeutics
7.2. Pasireotide (Signifor): Recordati
8. Cushing's Syndrome Emerging Therapies
8.1. Key Cross Competition
8.2. Osilodrostat: Recordati
8.3. Relacorilant: Corcept Therapeutics
9. Cushing's Syndrome Market Size
10. 7MM: Country-Wise Market Analysis
10.1.United States Market Size
10.2.Germany Market Size
10.3. France Market Size
10.4.United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
13. Cushing's Syndrome Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight